<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Considerations for using genetic material in medical nanotechnology</style></title><secondary-title><style face="normal" font="default" size="100%">Health Law Review</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Fall, 2004</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.law.ualberta.ca/centres/hli/pdfs/hlr/v12_3/12-3-05%20Tyshenko.pdf</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">3</style></volume><pages><style face="normal" font="default" size="100%">19-23</style></pages><isbn><style face="normal" font="default" size="100%">1188-8725</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The market for future therapeutics, molecular nanotechnology products, medical devices and diagnostic tools promises to be substantial. The use of DNA (Deoxyribonucleic acid) derived tools in the fields of molecular and medical nanotechnology promises a plethora of medical benefits with potential applications for drug delivery, health diagnostics and gene therapy. However, underlying the positive applications of this emerging technology is the potential for unknown hazards. As little has been mentioned of possible problems associated with using genetic material in the nanotechnology field to target drug delivery to specific cells and tissues so far, the technology should be regulated.</style></abstract><work-type><style face="normal" font="default" size="100%">Journal Article</style></work-type></record></records></xml>